Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589456 · ClinicalTrials.gov registry record
Establishment of a PDT Patient Registry
A clinical trial, sponsored by Concordia Laboratories.
- Terminated
- Registry status
- 22
- Enrollment target
NCT03589456: Clinical Trial study, sponsored by Concordia Laboratories.
NCT03589456 is a clinical trial that was terminated before completion, run by Concordia Laboratories. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03589456 was terminated before completion, sponsored by Concordia Laboratories.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This is a non-intervention patient registry to gather data on the use of photodynamic therapy under real-life conditions. It will involve up to 20 sites in USA.
Primary Outcome
Collection of information on patient characteristics, disease sites, and utilization of prior or combined treatments to evaluate the impact of these parameters on the treatment outcome
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2020-01-15 |
Why NCT03589456 stopped before completion
NCT03589456 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT03589456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03589456 about?
NCT03589456 is a clinical study titled "Establishment of a PDT Patient Registry". This is a non-intervention patient registry to gather data on the use of photodynamic therapy under real-life conditions. It will involve up to 20 sites in USA.
What is the current status of trial NCT03589456?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2019-01-18. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT03589456?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT03589456?
This trial is sponsored by Concordia Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI